A leading pharmaceutical company has been evaluating GEA Lyophil’s Lyoplus mass spectrometer to provide essential data from within the freeze dryer itself.
The unnamed company has confirmed a number of benefits, including the ability to detect very small silicone oil leaks inside the dryer; the ability to monitor the moisture content within the freeze drying chamber; identifying the end point of primary and secondary drying; and a much easier and faster leak detection.
The pharmaceutical company is already operating a Lyoplus system and will shortly have it fitted to five additional freeze dryers. By the end of 2012 it expects to have more systems in operation.
Lyoplus is able to work alongside any existing PLC/SCADA system as a stand-alone unit or fully integrated within the control system. It can also be operated independently as a monitoring system that does not interfere with any qualified processes.
GEA Lyophil says Lyoplus performs three tests – silicone oil detection, moisture content and chamber leakage – in one single unit, thereby improving productivity; reducing power consumption and the environmental impact of the process; and saving time and money.
Lyoplus performs three tasks in one unit
Improving productivity and reducing environmental impact
You may also like
Manufacturing
Aseptic spray drying: Transforming biotherapeutics for a new era
Read moreWith interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
Trending Articles
Relevant companies
You may also like
Manufacturing
Aseptic spray drying: Transforming biotherapeutics for a new era
With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
Manufacturing
Continuous innovation: redefining the future of pharmaceutical manufacturing
In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced